search
Back to results

An Open-Label Trial of PEMF Therapy [Provant Infinity Therapy System] for Home Use in Postoperative Pain

Primary Purpose

Postoperative Pain

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Provant Infinity Therapy System
Sponsored by
Regenesis Biomedical, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain

Eligibility Criteria

22 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 1. Subject is ≥ 60 days postoperative. 2. Subject's average chronic postoperative pain over the preceding week is ≥4 and <9, based on the 11-point NPRS (0-10) at the Screening Visit.

    3. Subject's age is greater than or equal to 22 years and less than 80 years of age.

    4. Subject is willing and able to give written informed consent and to comply with all parts of the study protocol.

    5. Female subjects must be postmenopausal, surgically sterile, abstinent, or, if of childbearing potential, practicing (or agrees to practice) an effective method of birth control if they are sexually active for the duration of the study. Effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier methods, and/or male partner sterilization.

Exclusion Criteria:

  • 1. Subject has a history of previous solid organ transplant or severe renal disease (i.e. estimated creatinine clearance <30 mL/min).

    2. Subject has previous or current history of primary or tertiary hyperparathyroidism, hypercalcemia, psychiatric disorder, alcohol dependency, Hepatitis B or C, or HIV infection.

    3. According to the judgment of the Investigator, subject has clinically significant cardiovascular disease within 6 months prior to screening (unstable or poorly controlled hypertension, transient ischemic attack, myocardial infarction, unstable angina, arrhythmia, cardiac surgery, stent placement or angioplasty, or congestive heart failure).

    4. Subject has a history of any uncontrolled medical illness that, in the investigator's judgment, places the subject at unacceptable risk for enrollment in a research trial with pulsed electromagnetic field therapy.

    5. Subject requires or anticipates the need for surgery (other than minor outpatient surgical procedures, such as dental or minor cosmetic procedures) or extended travel during the treatment period.

    6. Subject has received any investigational drug or device within 30 days prior to the Screening Visit.

    7. Subject has a history of malignancy within the past 5 years in the treatment area.

    8. Subject has severe mental health or psychiatric disorder that would interfere with study performance and/or assessments in the opinion of the Investigator.

    9. Subject has a known history of drug or alcohol abuse within one year prior to the Screening Visit.

    10. Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s).

    11. Subject is currently pregnant or planning to become pregnant prior to Week 8.

    12. Subject is unwilling or unable to follow study instructions or comply with the treatment regimen, diary documentation, and study visits.

Sites / Locations

  • Physician's Research Group
  • Valley Clinical Research
  • Lake Internal Medicine Associates
  • Palm Research Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Provant Infinity Therapy

Arm Description

Open-label treatment with Provant Infinity Therapy

Outcomes

Primary Outcome Measures

Device Use Questionnaire
4 question questionnaire on device usage (total of all responses will be counted at the end of the study); response will require a "Yes" or "No" answer

Secondary Outcome Measures

Device Feedback Questionnaire
5 question questionnaire about the study device; device use questions will be open text, "Yes" or "No" answers or rated from "Extremely Easy/Extremely Comfortable" to "Extremely Difficult/Extremely Uncomfortable"
Numeric Pain Rating Scale (NPRS)
11-point numerical rating scale for pain (0 = no pain to 10 = worst possible pain)

Full Information

First Posted
February 21, 2020
Last Updated
April 2, 2020
Sponsor
Regenesis Biomedical, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04300907
Brief Title
An Open-Label Trial of PEMF Therapy [Provant Infinity Therapy System] for Home Use in Postoperative Pain
Official Title
An Open-Label Trial of PEMF Therapy [Provant Infinity Therapy System] for Home Use in Postoperative Pain
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Due to COVID-19
Study Start Date
March 1, 2020 (Actual)
Primary Completion Date
March 24, 2020 (Actual)
Study Completion Date
March 24, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Regenesis Biomedical, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A study of the use of the Provant Infinity Therapy System when treatment is administered 30 minutes twice daily for 8-weeks (56 days ± 3 days) at home for postoperative pain.
Detailed Description
This is an 8-week (56 days ± 3 days), multi-center, open label clinical trial conducted on subjects with chronic postoperative pain. Eligible subjects will include those between 22 and 80 years of age with chronic postoperative pain at least 60 days following surgery. At the Screening Visit, eligible subjects will have an average weekly pain score, over the last 7 days of ≥4 and <9 based on the 11-point NPRS (0-10) and will verbally confirm they have chronic postoperative pain from surgery ≥ 60 days prior . After signing Informed Consent and verifying subject eligibility for the trial (including a pain score assessment using the NPRS), subjects will have demographic information, medical/surgical history and medication use reviewed and recorded. An abbreviated physical examination, including height and weight, will be performed. A urine pregnancy test will be performed on women of childbearing potential. Screening and Baseline (Day 0) / Enrollment may occur on the same day. During the Enrollment visit, subjects will receive study device training and be dispensed a study device with instructions to self-treat twice daily (morning and evening; 8am ± 2 hours and 8pm ± 2 hours) for 8 weeks (56 days ± 3 days). If Screening and Enrollment are not on the same day, subjects returning to the clinic for Baseline (Day 0) will have an additional review of eligibility, medical history, adverse events and concomitant medications prior to device training and dispensation. Subjects will receive a telephone call at Week 2 / Day 14 (±3 days). During the phone call subjects will have adverse events, and concomitant medications reviewed. Average weekly pain score (using the NPRS), Patient Global Impression (PGI), Treatment Satisfaction and Device Use questions will be captured. Subjects will receive a telephone call at Week 4 / Day 28 (±3 days). During the phone, call subjects will have adverse events, and concomitant medications reviewed. Average weekly pain score (using the NPRS), Patient Global Impression (PGI), Treatment Satisfaction and Device Use questions will be captured. Subjects will receive a telephone call at Week 6 / Day 42 (±3 days). During the phone, call subjects will have adverse events, and concomitant medications reviewed. Average weekly pain score (using the NPRS), Patient Global Impression (PGI), Treatment Satisfaction and Device Use questions will be captured. At the Week 8 / Day 56 (±3 days) End of Study Visit, subjects will have adverse events and concomitant medications reviewed. Average weekly pain score (using the NPRS), Patient Global Impression (PGI), Treatment Satisfaction and Device Use and Feedback questions will be captured and the study device will be returned.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
open-label
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Provant Infinity Therapy
Arm Type
Experimental
Arm Description
Open-label treatment with Provant Infinity Therapy
Intervention Type
Device
Intervention Name(s)
Provant Infinity Therapy System
Intervention Description
Treatment with the Provant Infinity Therapy System, PEMF device
Primary Outcome Measure Information:
Title
Device Use Questionnaire
Description
4 question questionnaire on device usage (total of all responses will be counted at the end of the study); response will require a "Yes" or "No" answer
Time Frame
Week 8
Secondary Outcome Measure Information:
Title
Device Feedback Questionnaire
Description
5 question questionnaire about the study device; device use questions will be open text, "Yes" or "No" answers or rated from "Extremely Easy/Extremely Comfortable" to "Extremely Difficult/Extremely Uncomfortable"
Time Frame
Week 8
Title
Numeric Pain Rating Scale (NPRS)
Description
11-point numerical rating scale for pain (0 = no pain to 10 = worst possible pain)
Time Frame
Weeks 2, 4, 6 and 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. Subject is ≥ 60 days postoperative. 2. Subject's average chronic postoperative pain over the preceding week is ≥4 and <9, based on the 11-point NPRS (0-10) at the Screening Visit. 3. Subject's age is greater than or equal to 22 years and less than 80 years of age. 4. Subject is willing and able to give written informed consent and to comply with all parts of the study protocol. 5. Female subjects must be postmenopausal, surgically sterile, abstinent, or, if of childbearing potential, practicing (or agrees to practice) an effective method of birth control if they are sexually active for the duration of the study. Effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier methods, and/or male partner sterilization. Exclusion Criteria: 1. Subject has a history of previous solid organ transplant or severe renal disease (i.e. estimated creatinine clearance <30 mL/min). 2. Subject has previous or current history of primary or tertiary hyperparathyroidism, hypercalcemia, psychiatric disorder, alcohol dependency, Hepatitis B or C, or HIV infection. 3. According to the judgment of the Investigator, subject has clinically significant cardiovascular disease within 6 months prior to screening (unstable or poorly controlled hypertension, transient ischemic attack, myocardial infarction, unstable angina, arrhythmia, cardiac surgery, stent placement or angioplasty, or congestive heart failure). 4. Subject has a history of any uncontrolled medical illness that, in the investigator's judgment, places the subject at unacceptable risk for enrollment in a research trial with pulsed electromagnetic field therapy. 5. Subject requires or anticipates the need for surgery (other than minor outpatient surgical procedures, such as dental or minor cosmetic procedures) or extended travel during the treatment period. 6. Subject has received any investigational drug or device within 30 days prior to the Screening Visit. 7. Subject has a history of malignancy within the past 5 years in the treatment area. 8. Subject has severe mental health or psychiatric disorder that would interfere with study performance and/or assessments in the opinion of the Investigator. 9. Subject has a known history of drug or alcohol abuse within one year prior to the Screening Visit. 10. Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s). 11. Subject is currently pregnant or planning to become pregnant prior to Week 8. 12. Subject is unwilling or unable to follow study instructions or comply with the treatment regimen, diary documentation, and study visits.
Facility Information:
Facility Name
Physician's Research Group
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85206
Country
United States
Facility Name
Valley Clinical Research
City
Northridge
State/Province
California
ZIP/Postal Code
91325
Country
United States
Facility Name
Lake Internal Medicine Associates
City
Eustis
State/Province
Florida
ZIP/Postal Code
32726
Country
United States
Facility Name
Palm Research Center
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89128
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

An Open-Label Trial of PEMF Therapy [Provant Infinity Therapy System] for Home Use in Postoperative Pain

We'll reach out to this number within 24 hrs